Adult Oncology Clinical Trials

HER2-Negative Breast Cancer Clinical Research

Study: AZD5305

EvoPAR-Breast01: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer.

Patients with diagnosis of HR-positive, HER2-negative advanced breast cancer, BRCA1, BRCA2, or PALB2m positive mutations.

Study: STML-ELA-0422

ELEGANT: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study.

ER+/ HER2-negative early stage resected invasive breast cancer without evidence of recurrence or distant metastases, considered at high risk of recurrence at initial staging, who have received at least 24 months but not more than 60 months of endocrine therapy. With no history of any prior invasive breast cancer.

Study: S2206

Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.

Patients with diagnosis of stage II or III breast cancer ER/PR +, HER2 negative, treatment naïve. Not locally recurrent breast cancer.

Triple Negative Breast Cancer Clinical Research

Study: A012103

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy.

Patients with diagnosis of TNBC with prior T1cN1-2 or T2-4N0-2 disease, no residual invasive disease, post-≥6 cycles of neoadjuvant chemotherapy + pembrolizumab.

Study: GS-US-595-6184

ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.

Sacituzumab govitecan + pembrolizumab vs. physician’s choice in residual invasive TNBC post-neoadjuvant therapy and surgery.

Breast Cancer Research: DNA, Precision Oncology, Biobanking, and Other Therapies

Study: MCI/FAU Minorities Biobank (Solid tumors)

All patients with archived solid tumor tissue or those undergoing diagnostic procedures (such as biopsies) or surgical interventions can participate in the voluntary donation of their specimens.

MCIFAU Biobank: Patients scheduled for biopsy or surgery, and consenting to contribute leftover tissue to the biobank, will provide clinical data including demographics, tumor type, stage, treatment history, molecular characteristics, and survival outcomes.

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Patients must completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months.

Early-stage Lung Cancer.

Study: A081801

ALCHEMIST Chemo-IO (ACCIO) Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC Must be EGFR (-) & ALK (-)

Completely resected stage IIA, IIB IIIA or IIIB NSCLC, in the last 30-77 days, EGFR(-), ALK(-), PD-L1 tested. Treatment naïve.

Study: NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.

Patients with non-operable or who refuse surgery, Stage IIB or III, node positive, NSCLC, with documented PD-L1. Patients with AGA mutations at registration are eligible, and can be treated with consolidation systemic therapy. No prior RT. T3-4N0 or T0N1-3 patients not eligible.

Advanced/Metastatic Non-Small Cell Lung Cancer

Study: CO45042

Krascendo 2: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Patient with diagnosis of advanced or metastatic non squamous NSCLC, KRAS G12C positive that is not eligible for curative surgery and/or definitive chemoradiotherapy, treatment naïve in the advanced/metastatic setting. With no known concomitant second oncogenic driver with available targeted treatment.

Study: CA224-1093

RELATIVITY1093: A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%.

Stage IV or recurrent Non-Small Cell Lung Cancer (Non-Squamous), PD-L1 >1%, No Actionable Mutations, treatment naïve in the metastatic setting.

Study: M25-274

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Patients with c-Met overexpressing NSCLC, locally advanced or metastatic. No Adenosquamous or neuroendocrine histology, or sarcomatoid features. No Actionable EGFR mutations (Other AGA are permitted) No prior c-Met treatments or docetaxel.

Study: SWOG - Lung-MAP

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer.

EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase II/III multi-sub-study trial under a hybrid Master Protocol for Stage IV or recurrent/progressive NSCLC with no curative options.

Study: S1900G

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).

Advanced NSCLC with EGFR and MET alterations, involving local or distant spread.

Basket Clinical Trials

Study: BiPAVE-001

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors.

Part B - Cohort B: NSCLC non-squamous, no prior lines or TKI only

Part B - Cohort G: Treatment-naïve resectable squamous or non-squamous NSCLC.

Slot request required

Diagnosis of solid tumor and metastatic disease or locally advanced disease that is not amenable to local therapy.

Study: SGNB6A-001

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001)

Part D - D2: 1L NSCLC PD-1 Naive (TPS <1%): SV + Pembro D3 : 1L NSCLC : SV + Pembro + Carbo

Slot request required

Stage IV Non-Small Cell Lung cancer, no Large cell neuroendocrine tumors nor Small Cell Elements. D1/D2: TPS tested, EGFR (-), ALK (-), treatment naïve for locally advanced or metastatic setting D3: EGFR (-), ALK (-), treatment naïve, for locally advanced or metastatic setting, eligible for carboplatin treatment.

Study: VMO-01C

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma. With documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

(iii) Lung
(iv) Mesothelioma
(vi) any NTRK1+ tumors

Patient with a solid tumor malignancy, not responsive to SOC or had progressed following SOC and for which there is no approved or curative therapy. TrkA protein overexpression OR (ii). with documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Patients must completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months.

Study: MCI/FAU Minorities Biobank (Solid tumors)

All patients with archived solid tumor tissue or those undergoing diagnostic procedures (such as biopsies) or surgical interventions can participate in the voluntary donation of their specimens.

MCIFAU Biobank: Patients scheduled for biopsy or surgery, and consenting to contribute leftover tissue to the biobank, will provide clinical data including demographics, tumor type, stage, treatment history, molecular characteristics, and survival outcomes.

Study: NRG-BN003

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma.

Patient with diagnosed WHO Grade II Unifocal Meningioma newly diagnosed, gross totally resected, no prior RT/.

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

On Hold

About the study: Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Patients must completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months.

Study: RP1-104

IGNYTE-3: Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment.

Patients with diagnosis of Unresectable or metastatic Stage IIIb through IV cutaneous melanoma, Confirmed disease progression (PD) on an anti-PD-1 antibody treatment and an anti-CTLA-4 antibody treatment. No More than 2 lines of systemic therapy for advanced melanoma. If BRAF (+) previously treated.

Basket Clinical Trials

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

On Hold

Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months.

Study: VMO-01C

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma. With documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor. (vi) any NTRK1+ tumors.

Patient with a solid tumor malignancy, not responsive to SOC or had progressed following SOC and for which there is no approved or curative therapy. TrkA protein overexpression OR (ii). with documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

CNS

Study: NRG-BN003

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma.

Patient with diagnosed Unifocal Meningioma newly diagnosed WHO Grade II, gross totally resected, no prior RT.

Lung

Study: NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.

Patients with diagnosis of non-operable or who refuse surgery, Stage IIB or III, node positive, NSCLC, with known PD-L1 status prior to registration. Patients with EGFR/ALK/other driver mutation at registration are eligible, and can be treated with consolidation systemic therapy.

No prior RT. T3-4N0 or T0N1-3 not eligible.

GU

Study: NRG-GU012

SAMURAI: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial.

Patient with diagnosis of renal cell carcinoma, Node-positive unresectable or metastatic. Patients must have IMDC intermediate (1-2 factors) or poor risk disease (>= 3 factors).Candidate for standard of care therapy with either immuno-oncology (IO)-IO or IO-VEGF combination regimen. Primary renal tumor measuring 20 cm or less in anterior to posterior dimension.

GYN

Study: NRG-GY037

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer.

Newly diagnosed histologically confirmed FIGO (2018) Stage IIIA(T3aN0), IIIB (T3bN0); Stage IIIC1 (T3aN1, T3bN1) IIIC2 (T3aN2, T3bN2); IVA Squamous cell, adenocarcinoma, adenosquamous cervical cancer.

Basket Clinical Trials

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

On Hold

Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Patients must completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months.

Pancreatic cancer

Study: PanCan Screening

A Registry for Pancreatic Cancer Screening in Patients with Known Genetic Mutations or Familial History.

High-risk pancreatic cancer cohort: ≥2 first-degree relatives with pancreatic cancer, OR pathogenic mutations (STK11, CDKN2A, Lynch, BRCA1/2, PALB2, ATM) with ≥1 affected first-degree relative, OR Peutz-Jeghers Syndrome (PJS) regardless of family history.

Study: S2433

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma.

Patients with diagnosis of unresectable and/or metastatic ductal adenocarcinoma of the pancreas KRAS and BRAF V600E wild type. No mutations in PTEN, NRAS, EGFR extracellular domain exons 1-16, no amplifications of HER2 and MET, and no gene fusions of RET, NTRK1, and ALK. Must have received only one line of prior systemic cytotoxic chemotherapy. No previous targeted therapy.

Gastric Cancer

Study: A022102

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.

Patients with unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma, with documented PD-L1 CPS.Treatment naïve for unresectable or metastatic disease.

Basket Clinical Trials

Study: VMO-01C

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma. With documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

(ii) Esophageal regardless TrkA percentage
(v) Pancreatic cancers regardless TrkA percentage
(vi) any NTRK1+ tumors

Patient with a solid tumor malignancy, not responsive to SOC or had progressed following SOC and for which there is no approved or curative therapy. TrkA protein overexpression OR (ii). with documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

Study: BiPAVE-001

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors.

Part B - Cohort E: CRC (1-2 prior lines)

Slot request required

Diagnosis of solid tumor and metastatic disease or locally advanced disease that is not amenable to local therapy.

Study: MCI/FAU Minorities Biobank (Solid tumors)

All patients with archived solid tumor tissue or those undergoing diagnostic procedures (such as biopsies) or surgical interventions can participate in the voluntary donation of their specimens.

MCIFAU Biobank: Patients scheduled for biopsy or surgery, and consenting to contribute leftover tissue to the biobank, will provide clinical data including demographics, tumor type, stage, treatment history, molecular characteristics, and survival outcomes.

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

On Hold

Survivors of colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Patients must completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months.

Study: A032103

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

About the study: Patients with diagnosis of muscle-invasive urothelial carcinoma of the urethra, bladder, ureter, or renal pelvis. No evidence of residual disease or metastasis, who underwent radical surgery and lymph node dissection, nephroureterectomy or ureterectomy

Study: NRG-GU012

SAMURAI: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

About the study: Patient with diagnosis of renal cell carcinoma, Node-positive unresectable or metastatic. Patients must have IMDC intermediate (1-2 factors) or poor risk disease (>= 3 factors).Candidate for standard of care therapy with either immuno-oncology (IO)-IO or IO-VEGF combination regimen. Primary renal tumor measuring 20 cm or less in anterior to posterior dimension

Study: MK5684-004

OMAHA-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)

About the study: Patients with diagnosis of metastatic adenocarcinoma of the prostate without small cell histology, who progressed on ADT (or post bilateral orchiectomy), within 6 months, and had prior treatment with PARPi or were deemed ineligible, that have not received a taxane-based chemotherapy for mCRPC or more than one NHA

Basket Clinical Trials

Study: MCI/FAU Minorities Biobank (Solid tumors)

All patients with archived solid tumor tissue or those undergoing diagnostic procedures (such as biopsies) or surgical interventions can participate in the voluntary donation of their specimens.

MCIFAU Biobank: Patients scheduled for biopsy or surgery, and consenting to contribute leftover tissue to the biobank, will provide clinical data including demographics, tumor type, stage, treatment history, molecular characteristics, and survival outcomes.

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

On Hold

About the study: Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease over the past 6 months

Study: VMO-01C

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma. With documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

(vi) any NTRK1+ tumors

About the study: Patient with a solid tumor malignancy, not responsive to SOC or had progressed following SOC and for which there is no approved or curative therapy. TrkA protein overexpression OR (ii). with documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

Study: MCI/FAU Minorities Biobank (Solid tumors)

All patients with archived solid tumor tissue or those undergoing diagnostic procedures (such as biopsies) or surgical interventions can participate in the voluntary donation of their specimens.

MCIFAU Biobank: Patients scheduled for biopsy or surgery, and consenting to contribute leftover tissue to the biobank.

Study: 25C60

Transforming Cancer Care in Florida: Integrative Cancer Survivorship – Synergizing Biomarkers, Clinical Trials, and Education to Prevent Recurrence and Second Cancers.

On Hold

Survivors of lung, breast, colorectal, or other solid tumor malignancies at high risk for recurrence or second primary cancer. Completed prior therapy within the last 5 years. No radiographic or clinical evidence of active disease in the past 6 months.

Study: VMO-01C

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma. With documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

(i) Head and Neck Cancers (including squamous cell carcinoma, salivary gland carcinoma and adenoid cystic carcinoma)
(ii) Esophageal,
(iii) Lung,
(iv) Mesothelioma,
(v) Pancreatic cancers,
(vi) any NTRK1+ tumors

Patient with a solid tumor malignancy, not responsive to SOC or had progressed following SOC and for which there is no approved or curative therapy. TrkA protein overexpression OR (ii). with documented NTRK1 gene fusion, or a tumor which has progressed due to NTRK1 mutation after treatment of a pan-Trk inhibitor.

Study: BiPAVE-001

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors.

Part B - Cohort B: NSCLC non-squamous, no prior lines or TKI only
Part B - Cohort G: Treatment-naïve resectable squamous or non-squamous NSCLC.
Part B - Cohort H: Treatment-naïve patients with resectable colon cancer

Slot request required.

Diagnosis of solid tumor and metastatic disease or locally advanced disease that is not amenable to local therapy.

Lymphoproliferative Disorders clinical trials

Study: ADCT-402-105

LOTIS-7: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Slots open loncastuximab tesirine + glofitamab

Relapsed/refractory B-NHL, ≥2 prior systemic regimens (dose-escalation) or ≥1 (dose-expansion), requiring systemic treatment.

Study: SPI-Bel-301

CRESCENDO: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma.

Paused for Phase II Part 1 completed 22APR2026

Patients with newly diagnosed, untreated histology-proven PTCL based on local pathology review, eligible for treatment with Belinostat, Pralatrexate, and CHOP.

Study: MK-1026-010

BELLWAVE-010: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy.

Part 2 pending to open July 2026

Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease, relapsed/refractory to at least 1 prior therapy.

Study: BGB-11417-302

Study title: A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)

Study: A041501

Study title: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

About the study: Newly diagnosed precursor B-cell ALL

Study: S2308

Study title: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Patients with diagnosis of classic follicular lymphoma (cFL) grade 1-3A per WHO-HAEM4R, low-tumor burden follicular lymphoma. Must not have had prior systemic therapy for follicular lymphoma. Radiation therapy for a previous diagnosis of early-stage follicular lymphoma is allowed

Plasma Cell Disorders

Study: 64407564MMY1001

MonumenTAL-1 Part 3: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma. No open slots at the moment.

Multiple myeloma with measurable disease, progressed within 6 months or refractory/non-responsive to the most recent therapy. Must have received ≥1 full treatment cycle per line, unless progressive disease was the best response.

Study: 64007957MMY3003

MajesTEC-4: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Patient newly diagnosed with Multiple Myeloma, and have received induction +/- consolidation, Must have received only one line of therapy and achieved at least a partial response. Must not have received any maintenance therapy. Should not have received any prior BCMA-directed therapy, or any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy

Study: 64007957MMY3005

MajesTEC-7: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

Patient newly diagnosed with Multiple Myeloma, and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT). Who have not received any prior therapy for multiple myeloma or smoldering myeloma

Myeloid Diseases

Study: 2215-CL-0203

A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy.

No slots available

AML (excluding APL) in CR1 (CRp/CRi) with FLT3/ITD mutation in bone marrow or blood. Enrolled <2 months post-final consolidation per local practice. Not proceeding to transplant.

Study: NCI-2022-07006

MYELOMATCH: Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Patients with previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS. Patients must be treatment naïve.

Study: MM1MDS-A01

A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Patients previously enrolled onto MYELOMATCH screening protocol, and must have been given a treatment assignment to MyeloMATCH to MM1MDS-A01 based on the presence of an actionable mutation.

Study: MM1YA-S01

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia

Patients previously enrolled onto MYELOMATCH screening protocol, and must have been given a treatment assignment to MyeloMATCH to MM1YA-S01 based on the presence of an actionable mutation.

Study: MM1YA-CTG01

A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial

Patients previously enrolled onto MYELOMATCH screening protocol, and must have been given a treatment assignment to MyeloMATCH to MM1YA-CTG01 based on the presence of an actionable mutation.

Study: MM1OA-S03

A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Patients previously enrolled onto MYELOMATCH screening protocol, and must have been given a treatment assignment to MyeloMATCH to MM1OA-S03 based on the presence of an actionable mutation.

Cell Therapy Research

Study: INCA34176-357

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

New-onset moderate/severe cGVHD, history of allo-HCT from any HLA-matched donor, with ≤1 prior allo-HCT.

Study: 68284528MMY4006

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma

Serious or life-threatening multiple myeloma per USPI, and where re-apheresis, re-manufacturing, or other anti-myeloma directed therapy is not considered feasible or adequate per treating physician discretion

Study: TSCAN-001

A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA-1 (TSC-100) or HA-2 (TSC-101) in HLA-A*02:01 Positive Patients Undergoing Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation

Patients preparing for allogeneic haploidentical donor transplantation with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphocytic leukemia (ALL), and HLA-A*0201 positive.

Blood and Marrow Transplant

Study: NMDP IRB-1999-0021

CIMBTR - Protocol For a Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries.

Any recipient of unrelated, related donor, or autologous HSC transplant at a CIBMTR center is eligible for the Research Database, including adults (with or without decision-making capacity) and children.

Study: NMDP IRB-1991-0002

CIBMTR Sample Repository - Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries.

Eligible donors include those who have donated or are scheduled to donate HCs or cellular therapy products for allogeneic recipients via marrow harvest or apheresis (adults and children, with or without decision-making capacity). Patients treated for marrow toxic injury at NMDP RITN centers are also eligible.